Arq vs ASP Isotopes
ARQ and ASPI side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARQ and ASPI compare
ASP Isotopes is the larger company, worth 1.9 times as much as Arq ($267M against $139M).
ASP Isotopes grew revenue faster over the last twelve months (573% versus 7.3% for Arq).
Arq keeps more of each dollar of sales as profit, with a net margin of −38.5% compared with −380% at ASP Isotopes.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARQ | ASPI |
|---|---|---|
| Size and price | ||
| Market cap | $139M | $267M |
| Share price | $3.18 | $1.74 |
| Change, 1 year | −14.1% | −80.4% |
| Change, 5 years | −54.4% | – |
| Beta (5Y) | 1.32 | 1.94 |
| Employees | 202 | 271 |
| StockData Score | ||
| Total score | 6 | 6 |
| Valuation score | 3 | 3 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 0 |
| Health score | 3 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.1× (better) | 8.6× |
| P/B | 0.8× (better) | 1.0× |
| P/FCF | 99.8× | – |
| FCF yield | 1.0% (better) | −31.3% |
| Fair value | $5.24 | $5.25 |
| Margin of safety | 39.3% | 66.9% (better) |
| Growth | ||
| Revenue growth (TTM) | 7.3% | 573% (better) |
| Revenue growth, 5Y average | 12.3% | – |
| Profitability | ||
| Gross margin | 32.1% (better) | 18.3% |
| Operating margin | −38.3% (better) | −321% |
| Net margin | −38.5% (better) | −380% |
| FCF margin | 1.1% (better) | −271% |
| Return on equity | −25.0% (better) | −80.9% |
| Return on invested capital | −18.2% (better) | −549% |
| Financial health | ||
| Debt / equity | 0.16 (better) | 0.23 |
| Interest coverage | −17.5× (better) | −25.3× |
| Current ratio | 1.20 | 3.87 (better) |
| Altman Z-score | 1.34 (better) | −0.22 |
| Piotroski F-score | 1 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 35.5% | 42.7% |
| Held by insiders | 21.1% | 10.7% |
| Insider net buying, 12 months | $524K (better) | −$7.7M |
| Short interest, % of float | 1.4% | 22.9% |
Go deeper
- ARQ stock overview
- ARQ income statement
- ARQ valuation and score
- ASPI stock overview
- ASPI income statement
- ASPI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.